Form 4: Moleculin Biotech CFO Reports Routine RSU Vesting and Tax-Related Share Disposition

Moleculin Biotech's Chief Financial Officer, Jonathan P. Foster, reported the vesting of 833 restricted stock units and the subsequent disposition of 203 shares for tax purposes on June 16, 2025.

Summary

• Jonathan P. Foster, Chief Financial Officer of Moleculin Biotech, Inc. (MBRX), reported transactions on June 16, 2025, related to his beneficial ownership.
• 833 restricted stock units (RSUs) converted into common stock on a one-for-one basis.
• 203 shares of common stock were disposed of to cover tax obligations upon the vesting of the restricted stock unit awards, at a price of $0.6852 per share.
• Following these transactions, Mr. Foster directly holds 11,993 shares of common stock and 230,684 restricted stock units.
• The 833 RSUs that vested represent the fourth and final annual installment of a 3,334 restricted stock unit grant originally made on June 16, 2021.

Sentiment

Score: 5

Explanation: The document reports a routine insider transaction related to executive compensation (RSU vesting and tax withholding), which is neutral in terms of company performance or outlook.

Positives

• The vesting of restricted stock units represents a routine compensation event for the Chief Financial Officer, aligning executive incentives with shareholder value through equity ownership.

Negatives

• No specific negative events or financial performance issues were disclosed in this routine insider transaction report.

Future Outlook

This Form 4 filing, detailing an insider transaction, does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This document is a routine SEC Form 4 filing, which reports changes in beneficial ownership by company insiders. It reflects an individual executive's compensation event rather than broader industry trends or competitive dynamics.

Related Party Transactions

• The vesting of restricted stock units and subsequent share disposition for tax purposes represents a routine compensation transaction between the company and its Chief Financial Officer, Jonathan P. Foster.

Stakeholder Impact

• Shareholders: This is a routine executive compensation event and is not expected to have a direct material impact on the company's operations or financial health beyond standard compensation practices.
• Employees, Customers, Suppliers, Creditors: No direct impact is indicated by this insider transaction report.

Key Dates

Keywords

Moleculin Biotech, MBRX, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Jonathan P. Foster, Chief Financial Officer, Executive Compensation, Share Disposition